We are live on ! Find out more
AZN icon

AstraZeneca

544 hedge funds and large institutions have $17.4B invested in AstraZeneca in 2018 Q3 according to their latest regulatory filings, with 60 funds opening new positions, 149 increasing their positions, 195 reducing their positions, and 48 closing their positions.

New
Increased
Maintained
Reduced
Closed

207% more call options, than puts

Call options by funds: $225M | Put options by funds: $73.5M

123% more capital inflows, than outflows

Capital inflows: $2.16B | Capital outflows: $967M

25% more first-time investments, than exits

New positions opened: 60 | Existing positions closed: 48

2% more funds holding

Funds holding: 531 → 544 (+13)

0.98% more ownership

Funds ownership: 13.16% → 14.14% (+0.98%)

24% less repeat investments, than reductions

Existing positions increased: 149 | Existing positions reduced: 195

40% less funds holding in top 10

Funds holding in top 10: 5 → 3 (-2)

Holders
544
Holders Change
+13
Holders Change %
+2.45%
% of All Funds
12.39%
Holding in Top 10
3
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-40%
% of All Funds
0.07%
New
60
Increased
149
Reduced
195
Closed
48
Calls
$225​M
Puts
$73.5​M
Net Calls
+$152​M
Net Calls Change
+$45​M

AZN Hedge Fund Activity: Q3 2018 in Review

544 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q3 2018, worth a combined $17.4B — up 21% from $14.3B a quarter earlier.

Buyers outnumbered sellers: 60 funds opened new AZN positions and 48 closed out — a net gain of 12 holders — while 149 added to existing stakes and 195 trimmed.

The largest buyer was Jennison Associates, adding an estimated $774M. The largest seller was Bank of America, cutting an estimated $123M.

  • 544 institutional investors held AstraZeneca (AZN) as of Q3 2018, up from 531 in Q2 2018.
  • Funds reported $17.4B of AstraZeneca stock for Q3 2018, up 21% quarter-over-quarter.
  • 60 funds opened new AstraZeneca positions in Q3 2018 and 48 closed out, a net change of +12 holders.
  • The largest AstraZeneca buyer in Q3 2018 was Jennison Associates, an estimated $774M added.
  • The largest AstraZeneca seller in Q3 2018 was Bank of America, an estimated $123M sold.

Based on aggregated 13F filings for Q3 2018.